Evestra
Evestra, Inc. is a privately held biopharmaceutical company based in Texas, dedicated to developing innovative products in women’s healthcare and oncology. With over ten years of experience, Evestra focuses on discovery, development, and commercialization of next-generation women’s healthcare technologies and products that address unmet needs. The company operates from facilities in San Antonio and Schertz, Texas, with a strategic approach that includes establishing an attractive portfolio of women’s healthcare products, strategic collaborations, and innovative R&D in oncology.
Industries
Nr. of Employees
small (1-50)
Patents
Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US-10738075-B2
View DetailsCytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US-10053485-B2
View DetailsCombination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
US-9850273-B2
View Details
Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US-10738075-B2
View DetailsCytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US-10053485-B2
View DetailsCombination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
US-9850273-B2
View DetailsProducts
Twice-yearly long-acting injectable contraceptive (development program)
A long-acting injectable contraceptive program intended for twice-yearly dosing, developed to expand access to modern contraception in underserved populations; program supported by grant funding.
Vaginal ring drug products (development pipeline)
Vaginal ring-based drug product projects at preclinical and clinical stages, developed using vaginal ring delivery technology and supporting GMP manufacturing.
First-in-class LIF inhibitor (preclinical oncology asset)
Preclinical oncology asset program targeting Leukemia Inhibitory Factor (LIF) for potential treatment of triple-negative breast cancer and other tumor types.
Kilo-scale steroidal API supply (offering)
Supply of kilo-scale steroidal active pharmaceutical ingredients manufactured for third-party customers and internal programs.
EC359
An innovative injectable anticancer product targeting LIF/LIFR to treat a variety of cancers.
EC313
An innovative orally-bioavailable mesoprogestin developed for the treatment of endometriosis.
Twice-yearly long-acting injectable contraceptive (development program)
A long-acting injectable contraceptive program intended for twice-yearly dosing, developed to expand access to modern contraception in underserved populations; program supported by grant funding.
Vaginal ring drug products (development pipeline)
Vaginal ring-based drug product projects at preclinical and clinical stages, developed using vaginal ring delivery technology and supporting GMP manufacturing.
First-in-class LIF inhibitor (preclinical oncology asset)
Preclinical oncology asset program targeting Leukemia Inhibitory Factor (LIF) for potential treatment of triple-negative breast cancer and other tumor types.
Kilo-scale steroidal API supply (offering)
Supply of kilo-scale steroidal active pharmaceutical ingredients manufactured for third-party customers and internal programs.
EC359
An innovative injectable anticancer product targeting LIF/LIFR to treat a variety of cancers.
EC313
An innovative orally-bioavailable mesoprogestin developed for the treatment of endometriosis.
Services
On-site manufacture of active pharmaceutical ingredients and finished drug products under cGMP and non-GMP conditions, including kilo-scale steroidal API production and vaginal ring product manufacturing.
Analytical method development, in-house testing and equipment to support formulation development, stability testing, and cGMP release for APIs and drug products.
Formulation development for multiple dosage forms including vaginal rings and long-acting injectable contraceptives, from preclinical development through early clinical stages.
Design and execution support for preclinical studies and Phase I/II clinical trials, including generation and publication of study data.
Strategic collaboration development, licensing and commercialization planning, and acquisition/management of non-dilutive funding and grants.
On-site manufacture of active pharmaceutical ingredients and finished drug products under cGMP and non-GMP conditions, including kilo-scale steroidal API production and vaginal ring product manufacturing.
Analytical method development, in-house testing and equipment to support formulation development, stability testing, and cGMP release for APIs and drug products.
Formulation development for multiple dosage forms including vaginal rings and long-acting injectable contraceptives, from preclinical development through early clinical stages.
Design and execution support for preclinical studies and Phase I/II clinical trials, including generation and publication of study data.
Strategic collaboration development, licensing and commercialization planning, and acquisition/management of non-dilutive funding and grants.
Expertise Areas
- Women’s health therapeutics
- Contraceptive development (long-acting injectables)
- Vaginal drug delivery and vaginal ring products
- Steroidal small-molecule medicinal chemistry
Key Technologies
- Vaginal ring drug delivery
- Long-acting injectable formulation technology
- Steroidal medicinal chemistry
- cGMP API manufacturing and scale-up
News & Updates
Evestra received a grant from the Bill and Melinda Gates Foundation to develop a twice-yearly injectable contraceptive to improve access to modern contraceptives.
Evestra completed a manufacturing facility and re-elected its board. The European partner Gedeon Richter became an equity shareholder as the company celebrated 10 years.
Evestra received a grant from the Department of Defense to develop first-in-class anticancer assets, supporting preclinical development.
The Mays Cancer Center at UT Health San Antonio and a local partner received a five-year, $3.3 million NIH grant for ovarian cancer research.
Evestra received a grant from the Bill and Melinda Gates Foundation to develop a twice-yearly injectable contraceptive to improve access to modern contraceptives.
Evestra completed a manufacturing facility and re-elected its board. The European partner Gedeon Richter became an equity shareholder as the company celebrated 10 years.
Evestra received a grant from the Department of Defense to develop first-in-class anticancer assets, supporting preclinical development.
The Mays Cancer Center at UT Health San Antonio and a local partner received a five-year, $3.3 million NIH grant for ovarian cancer research.